Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury

	Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury
	Yu, Dongsheng 1,2; Li, Mengwen 1,2; Tian, Youqing 3; Liu, Jun 1,2; Shang, Jing 1,2,4
刊名	life sciences
	2015-02-01
卷号	122 页码:15-25
关键词	Luteolin Myocardial ischemia/reperfusion injury Reactive oxygen species MAPK Mitochondrial Apoptosis
通讯作者	shang, j (reprint author), china pharmaceut univ, ctr drug screening, 24 tong jia xiang, nanjing 210009, jiangsu, peoples r china.
中文摘要	aims: luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ros-activated mapk pathways in ischemia/reperfusion injury is seldom reported. here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (miri) by inhibiting ros-activated mapk pathways. main methods: we exposed rat hearts into the left anterior descending coronary artery (lad) ligation for 30 min followed by 1 h of reperfusion. observations were carried out using electrocardiography; detection of hemodynamic parameters; and testing levels of lactate dehydrogenase (ldh), creatine kinase (ck), total superoxide dismutase (t-sod), and malondialdehyde (mda). mitogen-activated protein kinase (mapk) pathway was measured by western blot and transmission electron microscopy was applied to observe the myocardial ultrastructure. rat h9c2 cell in 95% n-2 and 5% co2 stimulated the miri. oxidation system mrna levels were measured by real-time pcr; mitochondrial membrane potential and apoptosis were measured by confocal microscopy and flow cytometry; western blot analysis was used to assay caspase-3, -8, and -9 and mapk pathway protein expression; the mapk pathway was inhibited using sb203580 (p38 mapk inhibitor) and sp600125 (c-jun nh2-terminal kinase inhibitor) before h9c2 cells were exposed to hypoxia/reoxygenation injury to show the modulation of the changes in ros generation, cell viability and apoptosis. key findings: in vivo, luteolin can ameliorate the impaired mitochondrial morphology, regulating the mapk pathway to protect miri. in vitro, luteolin can affect the oxidation system, mitochondrial membrane potential and mapk pathway to anti-apoptosis. significance: these results reveal a ros-mapk mediated mechanism and mitochondrial pathway through which luteolin can protect myocardial ischemia/reperfusion injury. (c) 2014 elsevier inc. all rights reserved.
英文摘要	aims: luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ros-activated mapk pathways in ischemia/reperfusion injury is seldom reported. here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (miri) by inhibiting ros-activated mapk pathways.
WOS标题词	science & technology ; life sciences & biomedicine
类目[WOS]	medicine, research & experimental ; pharmacology & pharmacy
研究领域[WOS]	research & experimental medicine ; pharmacology & pharmacy
关键词[WOS]	ischemia-reperfusion injury ; up-regulation ; infarct size ; in-vitro ; apoptosis ; cells ; protects ; hypoxia/reoxygenation ; kinase ; heart
收录类别	SCI
语种	英语
WOS记录号	WOS:000349508500003
内容类型	期刊论文
源URL	[http://ir.nwipb.ac.cn/handle/363003/5458]
专题	西北高原生物研究所_中国科学院西北高原生物研究所
作者单位	1.China Pharmaceut Univ, Ctr Drug Screening, Nanjing 210009, Jiangsu, Peoples R China 2.China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China 3.Jiangsu Union Tech Inst, Lianyungang TCM Branch, Lianyungang 222007, Peoples R China 4.Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Key Lab Tibetan Med Pharmacol & Safety Ev, Xining 810008, Peoples R China
推荐引用方式 GB/T 7714	Yu, Dongsheng,Li, Mengwen,Tian, Youqing,et al. Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury[J]. life sciences,2015,122:15-25.
APA	Yu, Dongsheng,Li, Mengwen,Tian, Youqing,Liu, Jun,&Shang, Jing.(2015).Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.life sciences,122,15-25.
MLA	Yu, Dongsheng,et al."Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury".life sciences 122(2015):15-25.